Last reviewed · How we verify
Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone
Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone is a Combination vasopressor and corticosteroid therapy Small molecule drug developed by University of Athens. It is currently in Phase 3 development for Cardiac arrest with refractory shock, Septic shock.
This is a combination therapy that uses vasopressin and epinephrine as vasoconstrictors, methylprednisolone and hydrocortisone as corticosteroids to improve hemodynamics and reduce inflammation during cardiac arrest or septic shock.
This is a combination therapy that uses vasopressin and epinephrine as vasoconstrictors, methylprednisolone and hydrocortisone as corticosteroids to improve hemodynamics and reduce inflammation during cardiac arrest or septic shock. Used for Cardiac arrest with refractory shock, Septic shock.
At a glance
| Generic name | Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone |
|---|---|
| Sponsor | University of Athens |
| Drug class | Combination vasopressor and corticosteroid therapy |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Emergency Medicine |
| Phase | Phase 3 |
Mechanism of action
Vasopressin and epinephrine act as potent vasoconstrictors to maintain blood pressure and organ perfusion during circulatory collapse. The corticosteroids (methylprednisolone and hydrocortisone) provide anti-inflammatory effects and may improve outcomes in shock states by stabilizing cellular membranes and reducing inflammatory mediator release. This combination addresses both the immediate hemodynamic crisis and the underlying inflammatory cascade.
Approved indications
- Cardiac arrest with refractory shock
- Septic shock
Common side effects
- Hypertension
- Tachycardia
- Hyperglycemia
- Immunosuppression
- Arrhythmias
Key clinical trials
- Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.
- VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial (PHASE3)
- Vasopressin, Epinephrine, and Steroids for Cardiac Arrest (PHASE3)
- Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone CI brief — competitive landscape report
- Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone updates RSS · CI watch RSS
- University of Athens portfolio CI
Frequently asked questions about Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone
What is Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone?
How does Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone work?
What is Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone used for?
Who makes Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone?
What drug class is Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone in?
What development phase is Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone in?
What are the side effects of Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone?
Related
- Drug class: All Combination vasopressor and corticosteroid therapy drugs
- Manufacturer: University of Athens — full pipeline
- Therapeutic area: All drugs in Critical Care / Emergency Medicine
- Indication: Drugs for Cardiac arrest with refractory shock
- Indication: Drugs for Septic shock
- Compare: Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone vs similar drugs
- Pricing: Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone cost, discount & access